Liège, Belgium, 30 November 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces an update on the clinical study progress for its two lead Estetrol (E4) based product candidates, Estelle® (E4 Freedom) and Donesta® (E4 Relief).
Liège, Belgium, 29 November 2017 – 18:00 – Regulated Information – Following press release issued on 30 October 2017, Mithra (Euronext Brussels: MITRA) today confirms, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 724,350 ordinary shares have been issued by the Company for an amount of EUR 2,478,594 as the result of the exercise of 439 subscription rights (warrants).
- Extended shelf-life offers competitive advantage over current tibolone-based products, including originator product Livial®
- Tibelia® is currently marketed in 5 countries through existing supply and license agreements, with further contracts and product launches planned in coming months
Liège, Belgium, 22 novembre 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today confirms the extended shelf-life of 36 months of its complex therapeutic product Tibelia®, as compared to 24 months for other currently available tibolone-based products.
- Bioequivalence study performed on commercial Myring™ batch produced at Mithra CDMO
- Data will form part of planned Myring™ FDA filing by US partner Mayne Pharma
Liège, Belgium, 17 November 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces the successful outcome of a confirmatory bioequivalence study performed on a commercial batch of Myring™ produced at the Mithra CDMO. The study results reconfirm that Myring™ is bioequivalent to Nuvaring®, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA).
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : firstname.lastname@example.org